MGC Pharma (ASX:MXC)
- Ticker 2:OTC:MGCLF
- CEO:Roby Zomer
MGC Pharma (ASX:MXC) Stock Price
Disclaimer: Past performance is not an indicator of future performance.
MGC Pharma (ASX:MXC) Company Overview
MGC Pharmaceuticals (ASX: MXC) is a biotech firm that is currently developing a number of cannabis-based medicinal products such as "CogniCann", which is intended to treat patients suffering from dementia and Alzheimer's.
The company's manufacturing facility in Slovenia recently received one of the European Union's first approvals to extract and develop Phytocannabinoid active pharmaceutical ingredients (API). This will give MGC a considerable competitive advantage as it pursues full vertical integration in the increasingly crowded biopharma market.
MGC Pharmaceuticals was also the first Australian cannabis company to be granted qualification for all of its' Phytomedicines from the European Medicines Agency, allowing it to apply for drug evaluation and registration of CogniCann, CannEpil, and any other medicinal cannabis products currently being developed.
CannEpil is another cannabis-based medicine developed by MGC that is intended to aid the sufferers of epilepsy regulate their symptoms. A growing amount of medical practitioners have already been granted approval to prescribe the drug to Australian patients.
- Address:1202 Hay Street, West Perth, WA 6005, Australia